Literature DB >> 16213139

Intermediate filament proteins participate in signal transduction.

Brian T Helfand1, Ying-Hao Chou, Dale K Shumaker, Robert D Goldman.   

Abstract

How timely transport of chemical signals between the distal end of long axonal processes and the cell bodies of neurons occurs is an interesting and unresolved issue. Recently, Perlson et al. presented evidence that cleavage products of newly synthesized vimentin, an intermediate filament (IF) protein, interact with mitogen-activated protein (MAP) kinases at sites of axon injury. These IF fragments appear to be required for the transport of these kinases to the cell body along microtubule tracks. The truncated vimentin is instrumental in signal propagation as it provides a scaffold that brings together activated MAP kinases (such as Erk 1 and Erk2), as well as importin beta and cytoplasmic dynein. The authors propose that this all-in-one transport complex has the extraordinary ability to travel towards the cell body and enter the nucleus where the kinases activate and influence gene expression so that a neuron can generate a timely response to injury.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16213139     DOI: 10.1016/j.tcb.2005.09.009

Source DB:  PubMed          Journal:  Trends Cell Biol        ISSN: 0962-8924            Impact factor:   20.808


  27 in total

1.  The soft framework of the cellular machine.

Authors:  D A Weitz; P A Janmey
Journal:  Proc Natl Acad Sci U S A       Date:  2008-01-23       Impact factor: 11.205

Review 2.  Introducing intermediate filaments: from discovery to disease.

Authors:  John E Eriksson; Thomas Dechat; Boris Grin; Brian Helfand; Melissa Mendez; Hanna-Mari Pallari; Robert D Goldman
Journal:  J Clin Invest       Date:  2009-07-01       Impact factor: 14.808

Review 3.  Anchoring junctions as drug targets: role in contraceptive development.

Authors:  Dolores D Mruk; Bruno Silvestrini; C Yan Cheng
Journal:  Pharmacol Rev       Date:  2008-05-15       Impact factor: 25.468

4.  Post-transcriptional regulation of fukutin in an astrocytoma cell line.

Authors:  Tomoko Yamamoto; Yoichiro Kato; Atsuko Hiroi; Noriyuki Shibata; Makiko Osawa; Makio Kobayashi
Journal:  Int J Exp Pathol       Date:  2012-02       Impact factor: 1.925

5.  Physiology, structure, and susceptibility to injury of skeletal muscle in mice lacking keratin 19-based and desmin-based intermediate filaments.

Authors:  Richard M Lovering; Andrea O'Neill; Joaquin M Muriel; Benjamin L Prosser; John Strong; Robert J Bloch
Journal:  Am J Physiol Cell Physiol       Date:  2011-01-05       Impact factor: 4.249

6.  Patterning of novel breast implant surfaces by enhancing silicone biocompatibility, using biomimetic topographies.

Authors:  S Barr; E Hill; A Bayat
Journal:  Eplasty       Date:  2010-04-26

7.  p21Waf1 expression is regulated by nuclear intermediate filament vimentin in neuroblastoma.

Authors:  Xénia Mergui; Marie-Line Puiffe; Dominique Valteau-Couanet; Marc Lipinski; Jean Bénard; Mounira Amor-Guéret
Journal:  BMC Cancer       Date:  2010-09-02       Impact factor: 4.430

8.  Inhibition of vimentin or beta1 integrin reverts morphology of prostate tumor cells grown in laminin-rich extracellular matrix gels and reduces tumor growth in vivo.

Authors:  Xueping Zhang; Marcia V Fournier; Joy L Ware; Mina J Bissell; Adly Yacoub; Zendra E Zehner
Journal:  Mol Cancer Ther       Date:  2009-03-10       Impact factor: 6.261

Review 9.  Nitric oxide and cyclic nucleotides: their roles in junction dynamics and spermatogenesis.

Authors:  Nikki P Y Lee; C Yan Cheng
Journal:  Oxid Med Cell Longev       Date:  2008 Oct-Dec       Impact factor: 6.543

10.  Biomphalaria glabrata transcriptome: cDNA microarray profiling identifies resistant- and susceptible-specific gene expression in haemocytes from snail strains exposed to Schistosoma mansoni.

Authors:  Anne E Lockyer; Jenny Spinks; Richard A Kane; Karl F Hoffmann; Jennifer M Fitzpatrick; David Rollinson; Leslie R Noble; Catherine S Jones
Journal:  BMC Genomics       Date:  2008-12-29       Impact factor: 3.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.